Study of the Immunogenicity of Killed Influenza Vaccine in Patients With Ovarian, Fallopian Tube, and Primary Peritoneal Cancer in Remission
- All subjects must have a histologic diagnosis of epithelial ovarian cancer or primary
peritoneal carcinoma. Time from completion of chemotherapy will be no more than 6
- If no clinical evidence of disease is present after diagnosis with Stage III or IV
disease and completion of primary surgery and chemotherapy, or, if no clinical
evidence of disease is present after completion of chemotherapy for a disease
recurrence diagnosed after a progression-free interval of at least 2 years, for
patients of any initial stage.
- Prior malignancy (except basal cell or squamous cell skin cancer) within the past
- Presence of active CNS disease.
- Active bacterial, viral or fungal infections.
- Chemotherapy, biologic therapy, or radiation therapy < 4 weeks prior to study entry.
- History of active autoimmunity or immunosuppression.
- Use of immunosuppressive drugs within 4 weeks prior to study entry. Patients may
receive chemotherapy or other immunosuppressive medications at the discretion of
their physician during the subsequent year after influenza vaccination without
exclusion from the study.
- Patients with tumors of low malignant potential (borderline tumors) will not be
- Prior influenza vaccination with the current vaccine.
- History of serious sensitivity to eggs, or previous influenza vaccine.
- Pregnant of breastfeeding subjects.